Liraglutide inhibits the development of colorectal cancer by regulating TGF-β/Smad3 signaling pathway and affecting epithelial-mesenchymal transition

Abstract Background Liraglutide, a glucagon-like peptide-1 receptor agonist commonly used in diabetes management, has shown potential anti-cancer effects across various malignancies. However, its role and underlying mechanisms in colorectal cancer (CRC) remain unclear. Method We investigated the eff...

Description complète

Détails bibliographiques

Auteurs principaux:	Xinjian Li, Minghu Fan, Rong Huang, Keqiang Wang, Hunan Huang
Format:	Artigo
Langue:	Inglês
Publié:	Springer 2025-07-01
Collection:	Discover Oncology
Sujets:	Liraglutide Epithelial-mesenchymal transition TGF-beta Smad3 Colorectal cancer
Accès en ligne:	https://doi.org/10.1007/s12672-025-03223-6
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!